Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.00 -0.78% 635.00 620.00 650.00 635.00 635.00 635.00 9,088 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.4 -1.0 - 377

Renalytix Ai Share Discussion Threads

Showing 201 to 224 of 625 messages
Chat Pages: Latest  13  12  11  10  9  8  7  6  5  4  3  2  Older
DateSubjectAuthorDiscuss
10/6/2020
08:34
Link to the study; httpS://www.medrxiv.org/content/10.1101/2020.06.01.20119552v2.full.pdf Conclusion; “In conclusion, a machine learned model combining plasma biomarkers and EHR data *significantly* improved prediction of adverse kidney outcomes over standard clinical models in patients with T2 DKD from two large academic medical centers.”
74tom
10/6/2020
07:58
Another significant step along the road... The target population is simply enormous at 12m. A 50% improvement on existing methods + the considerable moat that RENX are building = multi billion dollar potential value.
74tom
09/6/2020
15:25
Yo LS how ya hangin? I still have my book "Rockets and Satellites work like this from prize-giving" and Yep Guinness Aim in this as well. This is the list of holdings - they have top sliced FARN,AVCT,SYNG and GDR and letting the rest run - apart from some real dogs like C4XD, MNO, INX MSYS - it's done pretty well - after those cash ins and before EIS relief it's up 40% Access Intelligence Angle Aortech Avacta C4X Discovery Creo Creo Crossword Cyber Diaceutics Directa Plus Evgen Falanx Group Faron Genedrive Hardide I-Nexus Ixico Maestrano Maxcyte Microsaic Renalytix Synairgen The Panoply Trackwise Transense
toffeeman
09/6/2020
12:57
You sound like you were always passed over at school prize giving Tigger.Are Guiness in this one too?
longshanks
09/6/2020
08:40
Awards - nearly as relevant as a recommendation from IC
toffeeman
09/6/2020
08:29
Excellent news - it’s in very good company there :)
74tom
09/6/2020
00:13
Company has been nominated for the company of the year award, FWIWhTTps://smallcapnetwork.co.uk/2020-awards/?mc_cid=3dd40219ae&mc_eid=7e6c89d886
longshanks
06/6/2020
21:23
Indeed, very interesting few months coming up... Hopefully we’ll get an update on FractalDX this week as per the below from the 28th April RNS: “Provisional dates have been obtained for the required Court hearings of the Company's application, but they are subject to change and dependent on the Court's timetable. If the hearings go ahead on the provisional dates, the present timetable provides that the final hearing, at which it is hoped that the Court will make an order confirming the Capital Reduction, will take place on 9 June 2020. The Capital Reduction does not take effect until the Court's order is filed with and registered by Companies House. The Board intends to file the required documentation with Companies House on the business day following the final Court hearing and, subject to compliance with all procedural requirements, Companies House will usually register the documents on the same day. On the present timetable, which is subject to change and dependent on the Court's timetable, this would mean that the Capital Reduction would take effect on 10 June 2020.”
74tom
06/6/2020
10:44
Chart points the way.
scottishfield
02/6/2020
11:45
Yes agree it's not the easiest slide to read, but definitely based on 100k patient cohort, the key assumptions are in the below paragraph. "Of the 100,000 patient cohort in the model tested with KidneyIntelX, 18,000 patients were assumed to be flagged as “high-riskR21; and received additional medical management and preventive measures. When slowed progression rate owing to KidneyIntelX was assumed to be 20% compared to SOC, the NPV of savings due to slowed progression, delayed/avoided dialysis & transplants, and fewer crashes was estimated to range between $835 million and $1.297 billion over a 5-year time horizon for the most-stringent and least –stringent definitions of progression respectively (Figure 1). The estimated savings realized for the ‘StringentR17; definition of progression or “base case” were $1.153 billion (Figure 1)" With potential savings like that, healthcare bosses will be desperate to utilise the software...
74tom
02/6/2020
11:28
74tom thanks for that - when I looked at that slide I could not work out whether the cost base saving was for 100k individuals or the patient population...or it wasn't 100% clear to me - opportunity even bigger than I thought.
nimbo1
02/6/2020
11:15
Nice one Melody, I've been keeping an eye on GAN too and have been amazed to see it's progress. It was under the radar this time last year, trading at about 60p, now sitting at just under £5! RENX is further under the radar as far as I'm concerned. The potential is gigantic, the below slide from March provides some idea; httpS://renalytixai.com/wp-content/uploads/2020/03/BHA-Renalytix-KidneyIntelX-NKF-Poster-3.25.20-FINAL-002.pdf A NPV base case cost saving of $1.15b for 100k patients over 5 years. Bear in mind the target market size is 37m patients just in the US, so this saving represents only 0.27% of the US market... Extrapolating to 5% US market penetration, the base case saving would be $21b... Worldwide the target market is around 850m individuals, so the potential value here is astronomical. This has blue sky potential like very few companies I've come across, backed up by a stellar management / advisory board, science & background factors (increasing obesity etc). Should be a fun journey...
74tom
02/6/2020
10:48
Melody - good luck. My spreadsheet gives an approx market cap here of £2 bil with change - almost a 10 bagger potential. Quite a rare opportunity therefore but of course assumes everything goes perfectly... I also believe maxcyte another one worth looking at which gets no hype but is a great company masked as a dog because of the investment its been making over the years into carma - they plan to spin that off onto nasdaq in the next 6-12 months too which could transform the value.
nimbo1
02/6/2020
09:55
I've joined in here this am. Lots going on. Funded by the gains made on GAN - share price has gone ballistic since NASDAQ listing so fingers crossed for the same here. GLAH
melody9999
27/5/2020
17:13
No problem at all - agree that low key and high potential is a great combination (Anexo is another I've been adding this week that's in a similar bracket, but far lower potential than here). The fact that the Mount Sinai antibody test already has FDA EUA approval & they have high volume distribution nailed via Bio-Techne certainly puts the palaver over at Omega Diagnostics in the context.
74tom
27/5/2020
16:45
Thanks for that info 74tom. RENX is one of those low key stocks that I love. I have been buying a few shares over the last week or so. Think this will do well.
longshanks
27/5/2020
16:22
As a reminder for anyone who stumbles upon RENX and isn't aware that they own 25% of the equity in the below venture... httpS://www.nasdaq.com/press-release/bio-techne-and-kantaro-biosciences-announce-partnership-to-develop-and-scale "MINNEAPOLIS and NEW YORK, May 19, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test. Kantaro Biosciences is a joint venture between Mount Sinai Health System ("Mount Sinai") and Renalytix AI (LSE: RENX) formed exclusively to ensure that diagnostic tests for critical health challenges are accessible to all. The Mount Sinai COVID-19 serology test was one of the first widely published serology tests in the United States and has gained recognition as a trusted, high-performing assay and comparator for subsequent COVID-19 serology tests. Kantaro has partnered with Bio-Techne to develop a test kit based on the Mount Sinai test and to scale up, manufacture, sell and distribute these kits. Initial kit production capacity is expected to enable laboratories to conduct in excess of 10 million tests monthly in July, scaling to higher capacity in subsequent months. The two companies have formed a joint commercialization and distribution team to support rapid distribution of the assay. Mount Sinai was issued an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for clinical testing in its CLIA certified laboratory on April 15th. Based on this success, Bio-Techne and Mount Sinai have partnered to develop high-quality production test kits, based upon the Mount Sinai test, which can be manufactured and distributed globally at scale. Kantaro will lead regulatory processes with the intention of submitting the scaled assay for FDA EUA review in May. Kit shipments are expected to begin immediately following the receipt of FDA regulatory authorization. The IgG antibody test kit, an enzyme-linked immunosorbent assay or ELISA, is designed to measure the presence or absence of anti-COVID-19 antibodies in addition to measuring the titer (level) of antibodies a person has produced. It utilizes not one, but two virus antigens, the full-length Spike protein, and its Receptor Binding Domain, which is necessary for viral entry into cells, and is potentially linked with neutralization. The test kit will use a simple patient blood draw and is designed to be easily run by any laboratory in the world without costly proprietary equipment. The technology underlying the diagnostic test was created by internationally recognized virology and pathology teams from the Icahn School of Medicine at Mount Sinai. In a recent comparison of EUA tests published by the FDA (link), which assumed a 5% incidence of COVID-19 in the population, the "Mount Sinai Hospital Clinical Laboratory COVID-19 ELISA Antibody Test" was reported to show a Positive Predictive Value (the probability of disease if the test is positive) of 100% and a Negative Predictive Value (the probability of no disease if the test is negative) of 99.6%. Bio-Techne and Kantaro are in the process of validating the scaled assay and expect the data to confirm similar results. "Combining Mount Sinai's strengths in disease management, patient monitoring and clinical study design with Bio-Techne's capabilities as a fully integrated, world leading ELISA developer and manufacturer, allows us to co-develop and validate what we believe will be the highest quality and highest utility assay for COVID-19 in the world," commented Dave Eansor, Bio-Techne's Protein Sciences Segment President. "The assay not only identifies individuals with prior exposure to the COVID-19 virus; the two step test is designed to minimize false negative and false positive results while delivering valuable, quantitative information regarding the immunity state of previously infected people." "We are extremely excited to partner with Kantaro and Mount Sinai to launch what we believe will be a gold standard serology test for COVID-19," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. "The Bio-Techne, Mount Sinai and Kantaro teams are working around the clock to develop this test, and we are on track to achieve in approximately eight weeks what would typically take 18 months or more. As the world leader in ELISA assays, Bio-Techne has substantial capacity and the ability to scale production levels to support much of our nation's needs. We look forward to providing the world with critical information related to past exposure to the virus." "Antibody testing will be critical to providing patients and governments the essential information they need to help the world economies reopen and begin to recover from COVID-19," said Florian Krammer, PhD, Professor of Microbiology at Icahn School of Medicine. "Through Kantaro's partnership with Bio-Techne, we look forward to bringing this extremely high-quality test to every corner of the globe, so that COVID-19 can be monitored and isolated." The original Mount Sinai assay has been performed on more than 30,000 patient samples. Mount Sinai is studying the use of the technology to measure antibody titer in previously infected individuals, to support vaccine development, and to help evaluate emerging immunotherapies."
74tom
27/5/2020
12:14
True - either way there is some stock to shift here so it’s going to consolidate or drop a bit baring more news. I’m a buyer again on any falls - shot, medium and long term one of the most promising companies I’ve seen for significant valuation gains.
nimbo1
27/5/2020
11:18
Yes, and that's what the current forecasts from N+1 assume - a product achieving niche success. They highlight this in their January 8th note that raised the target price to £4.20; "We iterate that these projections barely scratch the surface of the potential market value an effective prognostic risk test could achieve in the estimated 37m US population of CKD patients" And this was before they became heavily involved with Covid-19 via antibody testing & pred-MAKER... Consolidation will be news dependant, it's only 15% higher than last December despite all of the positive news, so the price is hardly ahead of itself IMO.
74tom
27/5/2020
10:45
The way I read this situation is Renx could be a good buy at this level assuming its product becomes successful in a relatively niche way. I.e. it does a few 1000 tests per month for people who want the extra insight - that could support todays share price. revenue c.£50 mil a year with margins at c.40%. i.e. c£15 mil PAT and PE of 30. The upside is it becomes ingrained as part of the US healthcare system as the standard practice for kidney care...in which case you'll have a 10x +. Price needs to consolidate for a while imo.
nimbo1
27/5/2020
10:38
Faz, your comments are very glass half empty to say the least - it makes sense for RENX to list in the market where they operate & where the management team are based. I presume that they opted for an AIM listing to begin with because the product wasn't far enough along the path to commercialisation, two years on it clearly has made significant progress. For me the main reasons to list are; - Improved liquidity for the shares - Raise cash to grow the business - Increase awareness of the business in the market it is going to operate in Listing to attract a bidder doesn't make sense, why would anyone wait until a company's profile was raised before making a bid? The US markets have been toppy for ages and not reversed properly, most likely due to the amount of new cash added to the economy by the FED. Pharma / tech stocks have been well insulated and I don't see why that won't continue. Absolutely not a golden handshake, but for Pharma companies it is the best exchange in the world to list on, no doubt about that.
74tom
26/5/2020
22:27
Depends on the news flow imo - all this companies operations are in US. Certainly not much attention over here! FDA approval = good gains most of the time.
nimbo1
26/5/2020
21:42
Just to say a NASDAQ listing is not a golden handshake, and the US stock market looks very toppy right now. If it reverses a company would do well not to list. But if it does zero activity is more likely than zoom activity imo, but a listing can be useful if either fund raising is needed or attracting a bidder that perhaps would welcome a US market prescence.
faz
26/5/2020
16:41
Two very chunky delayed buys this afternoon - 12500 @ 4.35 and then a further 9984 @ 4.38. Next news could come any day, take your pick from; - FractalDX spin off update (pricing & timing) - Update on commencement of pred-MAKER project to study the links between Covid-19 and the Kidney's using RENX software - FDA EUA submission for the Mount Sinai antibody test (submission before the end of May according to the Bio-Techne RNS last week) - More details on the forthcoming NASDAQ listing - only announced a week ago but I doubt they'll be wasting any time (detail on pricing, amount to raise etc etc). - FDA Approval for KidneyIntelX - More partnerships / regulatory progress towards commercial launch This is a very exciting share which I'm very pleased to have discovered :)
74tom
Chat Pages: Latest  13  12  11  10  9  8  7  6  5  4  3  2  Older
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200810 12:17:12